StockData
Cogent Biosciences, Inc. logo

Cogent Biosciences, Inc. (COGT) stock

COGTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 2/30
$27.81−0.04 (-0.14%)

Close on Nov 18, 2026Market cap $4.83BP/E –Yield –

Cogent Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Cogent Biosciences's revenue for the twelve months ending Dec 31, 2020 was $7.87M, down 65.0% year over year. For fiscal 2020 it was $7.87M, down 65.0% from the year before.

Annual revenue

PeriodPeriod endValueChange
FY2020Dec 31, 2020$7.87M-65.0%
FY2019Dec 31, 2019$22.50M+131.1%
FY2018Dec 31, 2018$9.73M+16.4%
FY2017Dec 31, 2017$8.36M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2020Dec 31, 2020$0-100.0%
Q3 FY2020Sep 30, 2020$312.00K-69.4%
Q2 FY2020Jun 30, 2020$528.00K-83.2%
Q1 FY2020Mar 31, 2020$7.03M+130.3%
Q4 FY2019Dec 31, 2019$15.29M+301.8%
Q3 FY2019Sep 30, 2019$1.02M-50.1%
Q2 FY2019Jun 30, 2019$3.14M+88.4%
Q1 FY2019Mar 31, 2019$3.05M+37.5%
Q4 FY2018Dec 31, 2018$3.81M+79.2%
Q3 FY2018Sep 30, 2018$2.04M-12.4%
Q2 FY2018Jun 30, 2018$1.67M-19.9%
Q1 FY2018Mar 31, 2018$2.22M+21.5%
Q4 FY2017Dec 31, 2017$2.12M–
Q3 FY2017Sep 30, 2017$2.33M–
Q2 FY2017Jun 30, 2017$2.08M–
Q1 FY2017Mar 31, 2017$1.83M–

More Cogent Biosciences figures

See a number that looks wrong?